Top Story
- Press Release
Abbott Laboratories experienced a robust first quarter in 2024, driven primarily by its medical devices segment. This resulted in overall sales surpassing Wall Street forecasts and an updated, optimistic financial outlook for the year. The company reported a 2.2% increase in total sales year-over-year, reaching $10 [...]
Latest Stories
- Integrated Evidence Assessment & Planning
Featured Webinars
Practical AI: Adding Insight to the Patient Journey with Digital Phenotyping
Thursday, May 23, 2024
Sponsor: OM1
Insights from the 2024 Salary Survey Report by HealthEconomics.com
Wednesday, May 1, 2024
Webinar Host: Scientist.com
The live session will focus on the latest salary and bonus trends for professionals in the field, including a comprehensive overview [...]
Beyond Accelerated Approvals: External Control Arms
Wednesday, April 10, 2024
Sponsor: Cardinal Health
Delphi Panels: What Are They Good For?
Tuesday, March 12, 2024
Sponsor: Partnership for Health Analytic Research (PHAR)
Handpicked Promotions & Highlights
Latest in Catalyst News powered by BioPharmCatalyst
Sage Therapeutics SAGE date announcement
Sage Therapeutics already had five catalyst announcements coming up, but they added another one today. On April 30, 2024, it will announce top-line results for their recent Phase 2 trial for Dalzanemdor (SAGE-718) - (PRECEDENT). [...]
Read MoreTRACON Pharmaceuticals WINT earnings announcement
Windtree Therapeutics revealed their most recent quarterly earnings data for Q4. EPS was estimated to be -$0.94 and came in right around that value at -$0.95.
Closing price decreased significantly, falling $0.02 (-4.79%) to $0.40 [...]
Read MoreHepion Pharmaceuticals HEPA earnings announcement
Hepion Pharmaceuticals revealed their most recent quarterly earnings data, in which EPS ended up higher than estimates. EPS was estimated to be -$2.63 and the actual figure came in at -$2.42. Hepion Pharmaceuticals' EPS is [...]
Read MoreSearch HealthEconomics.com
Throw in a keyword, research topic, disease model or technology of interest